Promising Phase III Myeloma and NSCLC Trials, FDA Approval Sought in MZL, and More

Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes

Dr Sabari on Barriers to Biomarker Testing in NSCLC

Dr Backhus on Surgical Eligibility in Borderline Resectable NSCLC

Dr Herbst on the Importance of Multidisciplinary Collaboration in NSCLC